MRC Epidemiology Resource Centre, Southampton General Hospital, University of Southampton, Southampton, UK.
J Clin Densitom. 2010 Oct-Dec;13(4):462-6. doi: 10.1016/j.jocd.2010.05.008. Epub 2010 Jul 21.
Little is known about the impact of concomitant vitamin D deficiency on bone mineral density in hyperthyroidism. Therefore, we evaluated bone mineral measures in vitamin D-deficient and sufficient patients with hyperthyroidism. Thirty newly diagnosed consecutive patients with hyperthyroidism were included. Blood samples were used for measurement of calcium, phosphate, alkaline phosphatase, 25-hydroxy vitamin D [25(OH) D], and parathyroid hormone (PTH). Bone mineral density (BMD) was measured at the hip, spine, and forearm. The patients were divided into vitamin D-deficient (< 25 nmol/L) and vitamin D-sufficient groups (≥ 25 nmol/L). Eight (26.6%) patients had 25(OH) D levels less than 25 nmol/L, with mean ± standard deviation (SD) level of 16.5 ± 3.2 (vitamin D-deficient group 1), and the remainder had a mean ± SD of 46.0 ± 13.5 nmol/L (vitamin D-sufficient group 2). Serum-intact PTH levels were significantly higher in group 1 compared with those in group 2 (31.2 ± 16.3 vs 18.0 ± 13.1 pg/mL; p=0.041). In the vitamin D-deficient group, the mean BMD T-scores were in the osteoporotic range at hip and forearm (-2.65 ± 1.13 and -3.04 ± 1.3) and in the osteopenia range at lumbar spine (-1.83 ± 1.71). However, in vitamin D-sufficient group, the mean BMD T-scores were in the osteopenia range (-1.64 ± 1.0, -1.27 ± 1.6, and -1.60 ± 0.7) at hip, forearm, and lumbar spine, respectively. The mean BMD Z-scores were also significantly lower in vitamin D-deficient group compared with those in vitamin D-sufficient group. Finally, BMD values (gm/cm(2)) at the hip and forearm were significantly lower in the vitamin D-deficient group compared with those in the vitamin D-sufficient group. In conclusion, hyperthyroid patients with concomitant vitamin D deficiency had lower BMD compared with vitamin D-sufficient patients.
关于维生素 D 缺乏对甲状腺功能亢进症患者骨密度的影响知之甚少。因此,我们评估了维生素 D 缺乏和充足的甲状腺功能亢进症患者的骨矿物质测量值。纳入了 30 例新诊断的甲状腺功能亢进症连续患者。采集血样以测量钙、磷、碱性磷酸酶、25-羟维生素 D [25(OH)D]和甲状旁腺激素 (PTH)。测量髋部、脊柱和前臂的骨矿物质密度 (BMD)。患者分为维生素 D 缺乏组(<25nmol/L)和维生素 D 充足组(≥25nmol/L)。8 例(26.6%)患者 25(OH)D 水平低于 25nmol/L,平均±标准差(SD)水平为 16.5±3.2(维生素 D 缺乏组 1),其余患者平均±SD 为 46.0±13.5nmol/L(维生素 D 充足组 2)。与维生素 D 充足组相比,组 1 的血清完整 PTH 水平明显升高(31.2±16.3 比 18.0±13.1pg/mL;p=0.041)。在维生素 D 缺乏组中,髋部和前臂的平均 BMD T 评分处于骨质疏松范围(-2.65±1.13 和-3.04±1.3),腰椎处于骨量减少范围(-1.83±1.71)。然而,在维生素 D 充足组中,髋部、前臂和腰椎的平均 BMD T 评分分别处于骨量减少范围(-1.64±1.0、-1.27±1.6 和-1.60±0.7)。维生素 D 缺乏组的平均 BMD Z 评分也明显低于维生素 D 充足组。最后,与维生素 D 充足组相比,维生素 D 缺乏组的髋部和前臂的 BMD 值(gm/cm(2))明显较低。结论:与维生素 D 充足的患者相比,伴有维生素 D 缺乏的甲状腺功能亢进症患者的 BMD 较低。